Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

CASI Acquires Global Rights To CD19 T-Cell Therapy; Will Make $11.6 Million Investment

publication date: Jun 18, 2019

CASI Pharma, a US-China company, obtained global rights to an autologous anti-CD19 T-cell therapy developed by Juventas Cell Therapy of Tianjin City, China. Juventas has filed China INDs to test CNCT19 as a treatment for two leukemia and lymphoma indications. A CASI 80%-owned China subsidiary will invest $11.6 million in Juventas instead of an upfront payment. CASI will make development milestone payments and pay sales royalties, though details were not disclosed. Juventas will continue to develop CNCT19 with CASI's participation on the program's steering committee. More details....

Stock Symbol: (NSDQ: CASI)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.